DealForma

The deal and funding database built for biopharma. Curated deal comps, company profiles, pipelines, dedicated analyst support so you do better research faster

[DealForma @DealForma]

Biopharma therapeutics and platform financing activity in Q1 2026 reflected a strengthening IPO market alongside more selective follow-on and PIPE funding conditions.

Read our research

https://t.co/yi7uw2beDN

[DealForma @DealForma]

Biopharma therapeutics and platform financing activity in Q1 2026 reflected a strengthening IPO market alongside more selective follow-on and PIPE funding conditions.

Read our research

https://t.co/5KXdcCcaNG

[DealForma @DealForma]

Q1 2026 biopharma therapeutic and platform M&A shifted toward fewer, larger, and higher-quality acquisitions, with buyers prioritizing late-stage, commercially validated, and strategically differentiated assets.

Read our research
https://t.co/LwBMqFxWs7

[DealForma @DealForma]

We’re excited to share that Chris Dokomajilar, Founder & CEO of DealForma, will be speaking at the CELS Canada in the Valley Showcase 2026 on May 14.

Chris will lead a session titled “Biopharma Venture, Licensing, IPOs, and M&A Trends Through Q1 2026.”

https://t.co/5jrmK49EOg

[DealForma @DealForma]

WSJ cited DealForma data showing that China and Hong Kong companies accounted for 50% of large pharma in-licensing deals with at least $50 million upfront so far this year, underscoring rising global pharma interest in China-originated assets.

https://t.co/n8fHWwsFWZ

[DealForma @DealForma]

Our Q1 2026 review reflects a shift toward fewer, larger, higher-quality biopharma R&D partnerships, with stronger upfront capital deployment and sustained deal flow, reinforcing disciplined investment.

Read our research

https://t.co/LgdxBhfLo1

[DealForma @DealForma]

Early-stage biopharma funding rebounded in 2025, but Q1 2026 is mixed: softer at platform/preclinical, while Phase II–III remains resilient with dollars and check sizes holding near 2025 levels.

[DealForma @DealForma]

Biopharma and healthcare VC investment rebounded in 2025 to $55.1B (1,309 rounds), up from $48.4B in 2024, with biopharma specifically increasing to $28.6B. Momentum has carried into Q1 2026 with several large $100M+ rounds.

[DealForma @DealForma]

Big pharma in-licensing remains heavily skewed toward early-stage assets, with platform/discovery deals consistently making up ~60–70%+ of activity, rising to ~75% in 2026 YTD. Late-stage (Phase II–III) deals continue to represent only a small share.

[DealForma @DealForma]

ADC deal activity remained strong in 2025, with total value reaching ~$25.8B across 36 deals and median upfronts rising to ~$60M, signaling continued demand for high-quality assets. In 2026 YTD, activity is more muted (~$0.6B; 6 deals)

[DealForma @DealForma]

Big pharma in-licensing spend is heavily concentrated in oncology and biologics, with cancer driving the majority of upfront payments each year and biologics/antibodies/ADCs dominating modality spend (peaking at ~$9.7B in 2025).

[DealForma @DealForma]

Biopharma & medtech entered 2026 with selective momentum, with J.P. Morgan’s reports — powered by DealForma — highlighting strong licensing, M&A, and early IPO recovery.

Download the full reports for deeper insights.

https://t.co/rZtvj5ILGh

[DealForma @DealForma]

Upfront payments remain relatively compressed across stages (~$49M–$215M), but total deal value expands significantly in later stages, driven by milestones—peaking around ~$2.0B in Phase II and ~$1.3B in Phase III.

[DealForma @DealForma]

From 2023–2025, upfronts increased with stage, with later-stage deals commanding the highest premiums. In Q1 2026, this trend accelerated—Phase II median upfront hit ~$650M (single deal) and Phase I ~$180M—showing a shift toward fewer, high-value later-stage deals.

[DealForma @DealForma]

Large-cap biopharma dealmaking from 2024–2026 YTD is led by Eli Lilly, Roche, and Novartis in volume, with activity heavily skewed toward R&D partnerships over M&A. In terms of value, Novartis ($47.8B), AstraZeneca ($38.7B), and Eli Lilly ($38.0B) lead in in-licensing spend

[DealForma @DealForma]

Big pharma significantly increased sourcing from Chinese biopharma through 2025, with deal value rising to $68.7B across 19 large transactions, alongside growing upfront payments. In Q1 2026, China accounted for ~50% of big pharma deals and ~75% of upfront capital.

[DealForma @DealForma]

Licensing upfronts in 2025 were relatively balanced across regions (~$5.0B U.S., $5.1B EMEA, $7.3B APAC), with APAC leading overall. In Q1 2026, activity shifted sharply toward APAC, which generated $3.4B in upfronts, compared to $1.4B in the U.S. and just $0.4B in EMEA.

[DealForma @DealForma]

Neurology deal activity in 2025 was mixed, with weaker R&D partnerships offset by strong M&A growth, steady venture funding, and improved IPO activity, signaling confidence in later-stage and clinically validated assets.

Read our research

https://t.co/JkhAG1kZWO

[DealForma @DealForma]

China is leading large biopharma licensing deals in early 2026, with strong M&A activity and continued momentum showing sustained dealmaking and bigger payouts despite a slight dip in deal volume.

Read it here

https://t.co/waerjJjdAr

[DealForma @DealForma]

Biopharma licensing reached a record in 2025 with $259.6B total value and $17.1B upfront across 468 deals, and in Q1 2026 delivered $79.4B total value and $4.9B upfront vs. $61.6B and $5.2B in Q1 2025, with top upfronts led by CSPC/AstraZeneca ($1.2B) and RemeGen/AbbVie ($650M).